Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) reported that its preliminary unaudited fourth quarter 2015 results were impacted by softer-than-expected sales of the gastrointestinal business, as compared to previous guidance issued in December, driven by reductions in the wholesale and retail channel in reaction to Valeant's announcement of an agreement with Walgreens. Adjusted EPS was $2.50, for the quarter. On average, 20 analysts polled by Thomson Reuters expected the company to report profit per share of $2.61 for the quarter. Analysts' estimates typically exclude special items.
from RTT - Earnings http://ift.tt/1QZRl8I
via IFTTT
No comments:
Post a Comment